Anglo-US biotech Ottimo Pharma has completed a big early-stage biotech financing, raising $140 million for its PD-1 and VEGF targeting drug jankistomig for cancer. The London and Boston-based start-up ...
Epstein, formerly CEO of Seagen, joins as Chair & Chief Executive Officer Mehdi Shahidi, previously SVP and Chief Medical Officer at Boehringer Ingelheim, joins as Head of Development & Chief Medical ...
Ottimo Massimo is a dog, the dachshund to be more precise. It’s the dog of Cosimo Rondò di Piovasco, the Baron in the Trees by Italo Calvino. Between Cosimo and the dachshund there is a very special ...
LONDON and BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of ...
WALTHAM, Mass., January 08, 2026--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo ...
Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital, with additional investment from founding investor Medicxi Strengthens its leadership team with the appointments of industry veterans ...
[28 October 2024]: [London, UK/ Boston, US]: Ottimo Pharma, a private biotech company, announces the appointment of world class industry veterans David Epstein as Chair & Chief Executive Officer, ...
Dansey, a former senior executive at Pfizer and Seagen, Inc., brings extensive experience in immuno-oncology and drug development Board appointment reinforces Company's commitment to advancing ...
LONDON and BOSTON, Dec. 19, 2024 /PRNewswire/ -- Ottimo Pharma ("Ottimo"), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results